- Home
- RMAX vs NBTX Comparison
RMAX vs NBTX Comparison
Compare RMAX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- NBTX
- Stock Information
- Founded
- RMAX 1973
- NBTX 2003
- Country
- RMAX United States
- NBTX France
- Employees
- RMAX N/A
- NBTX N/A
- Industry
- RMAX Real Estate
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- RMAX Finance
- NBTX Health Care
- Exchange
- RMAX Nasdaq
- NBTX Nasdaq
- Market Cap
- RMAX 226.2M
- NBTX 201.9M
- IPO Year
- RMAX 2013
- NBTX 2020
- Fundamental
- Price
- RMAX $10.98
- NBTX $2.94
- Analyst Decision
- RMAX Hold
- NBTX Strong Buy
- Analyst Count
- RMAX 4
- NBTX 1
- Target Price
- RMAX $9.17
- NBTX $12.00
- AVG Volume (30 Days)
- RMAX 146.5K
- NBTX 66.4K
- Earning Date
- RMAX 02-20-2025
- NBTX 12-31-2024
- Dividend Yield
- RMAX N/A
- NBTX N/A
- EPS Growth
- RMAX N/A
- NBTX N/A
- EPS
- RMAX N/A
- NBTX N/A
- Revenue
- RMAX $311,818,000.00
- NBTX $45,220,186.00
- Revenue This Year
- RMAX N/A
- NBTX N/A
- Revenue Next Year
- RMAX $0.85
- NBTX N/A
- P/E Ratio
- RMAX N/A
- NBTX N/A
- Revenue Growth
- RMAX N/A
- NBTX 526.17
- 52 Week Low
- RMAX $6.94
- NBTX $2.76
- 52 Week High
- RMAX $14.31
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- RMAX 38.02
- NBTX 34.86
- Support Level
- RMAX $10.50
- NBTX $3.28
- Resistance Level
- RMAX $11.24
- NBTX $3.69
- Average True Range (ATR)
- RMAX 0.46
- NBTX 0.31
- MACD
- RMAX -0.20
- NBTX 0.02
- Stochastic Oscillator
- RMAX 18.75
- NBTX 19.35
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.